Condition: Metastatic Breast Cancer · ER-positive Breast Cancer · HER2-negative Breast Cancer · Sponsor: Olema Pharmaceuticals, Inc.
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.
This description comes directly from the study's public registry record.
OP-1250-003 Study · 415 651 7206 · medinfo@olema.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| University of California San Francisco Health | San Francisco, California, United States | Recruiting |
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Advent Health Hematology and Oncology | Orlando, Florida, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Health | Detroit, Michigan, United States | Recruiting |
| Regents of the University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Washington University, School of Medicine | St Louis, Missouri, United States | Recruiting |
| Ichan School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Atrium Health Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Henry-Joyce Cancer Clinic, The Vanderbilt Clinic | Nashville, Tennessee, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05508906